We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.
ITCI

Delisted

ITCI was delisted on the 1st of April, 2025.

Back to rankings

139 hedge funds and large institutions have $1.19B invested in Intra-Cellular Therapies Inc. in 2016 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 58 increasing their positions, 28 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more funds holding in top 10

Funds holding in top 10: 1 → 3 (+2)

107% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 28

81% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 16

56% more call options, than puts

Call options by funds: $22.7M | Put options by funds: $14.6M

46% more capital invested

Capital invested by funds: $812M → $1.19B (+$374M)

9% more funds holding

Funds holding: 127 → 139 (+12)

Holders
139
Holders Change
+12
Holders Change %
+9.45%
% of All Funds
3.71%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.08%
New
29
Increased
58
Reduced
28
Closed
16
Calls
$22.7M
Puts
$14.6M
Net Calls
+$8.1M
Net Calls Change
+$13.5M

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$28.1M
2
BB
BB Biotech
Switzerland
+$25.2M
3
O
OrbiMed
New York
+$21.3M
4
EC
EcoR1 Capital
California
+$8.8M
5
Norges Bank
Norges Bank
Norway
+$7.08M

Top Sellers

Rank Fund Capital Flow
1
VAM
Visium Asset Management
New York
-$31.4M
2
Millennium Management
Millennium Management
New York
-$22.1M
3
EAM
EverPoint Asset Management
Connecticut
-$12.6M
4
SAM
Senzar Asset Management
New York
-$8.56M
5
Renaissance Technologies
Renaissance Technologies
New York
-$6.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
CCP
26
Clough Capital Partners
Massachusetts
$8.76M +$920K +25,600 +13%
Geode Capital Management
27
Geode Capital Management
Massachusetts
$8.57M +$570K +15,863 +8%
BIM
28
BlackRock Investment Management
Delaware
$7.71M +$1.12M +31,060 +19%
Norges Bank
29
Norges Bank
Norway
$7.65M +$7.08M +197,000 New
RSCM
30
Rock Springs Capital Management
Maryland
$7.38M +$89.8K +2,500 +1%
TCM
31
Tekla Capital Management
Massachusetts
$7.29M – – –
CWG
32
C WorldWide Group
Denmark
$7.2M +$2.16M +60,000 +48%
Bank of New York Mellon
33
Bank of New York Mellon
New York
$6.88M +$1.02M +28,467 +19%
Point72 Asset Management
34
Point72 Asset Management
Connecticut
$6.57M -$2.2M -61,300 -27%
TCIM
35
TIAA CREF Investment Management
New York
$5.87M +$925K +25,751 +21%
JP Morgan Chase
36
JP Morgan Chase
New York
$5.68M +$3.56M +99,051 +210%
SAM
37
Senzar Asset Management
New York
$5.61M -$8.56M -238,300 -62%
GTC
38
Ghost Tree Capital
New York
$4.66M +$4.31M +120,000 New
RPAM
39
Rhenman & Partners Asset Management
Sweden
$4.46M – – –
Axa
40
Axa
France
$4.39M +$4.06M +113,065 New
SEI Investments
41
SEI Investments
Pennsylvania
$4.33M +$388K +10,798 +11%
Charles Schwab
42
Charles Schwab
California
$4.31M +$495K +13,782 +14%
BlackRock
43
BlackRock
New York
$4.04M +$52.3K +1,455 +1%
GPP
44
Great Point Partners
Connecticut
$3.88M +$3.59M +100,000 New
WRF
45
Waddell & Reed Financial
Kansas
$3.67M +$89.8K +2,500 +3%
DCM
46
Driehaus Capital Management
Illinois
$3.63M +$62.5K +1,740 +2%
Goldman Sachs
47
Goldman Sachs
New York
$3.51M +$2.35M +65,474 +263%
TAM
48
Tocqueville Asset Management
New York
$3.35M +$305K +8,500 +11%
FCM
49
Frontier Capital Management
Massachusetts
$3.18M -$4.01M -111,615 -58%
TA
50
Teachers Advisors
New York
$2.89M +$507K +14,115 +23%
1
2
3 4 5

ITCI Hedge Fund Activity: Q2 2016 in Review

139 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q2 2016, worth a combined $1.19B — up 46% from $812M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new ITCI positions and 16 closed out — a net gain of 13 holders — while 58 added to existing stakes and 28 trimmed.

The largest buyer was Vanguard Group, adding an estimated $28.1M. The largest seller was Visium Asset Management, cutting an estimated $31.4M.

  • 139 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q2 2016, up from 127 in Q1 2016.
  • Funds reported $1.19B of Intra-Cellular Therapies Inc. stock for Q2 2016, up 46% quarter-over-quarter.
  • 29 funds opened new Intra-Cellular Therapies Inc. positions in Q2 2016 and 16 closed out, a net change of +13 holders.
  • The largest Intra-Cellular Therapies Inc. buyer in Q2 2016 was Vanguard Group, an estimated $28.1M added.
  • The largest Intra-Cellular Therapies Inc. seller in Q2 2016 was Visium Asset Management, an estimated $31.4M sold.

Based on aggregated 13F filings for Q2 2016.